No Data
CSPC Innovation Pharmaceutical (300765.SZ): As of July 19, 2024, the company's total number of shareholders, including ordinary accounts and finance and securities lending credit accounts, was 16,352.
On July 22nd, Geely News reported that as of July 19, 2024, the number of shareholders of CSPC Innovation Pharmaceutical, which merged regular accounts and finance and securities lending credit accounts, reached 16,352 on the investor interaction platform.
A Look At The Fair Value Of CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765)
CSPC Innovation Pharmaceutical (300765.SZ): SYS6016, a respiratory syncytial virus mRNA vaccine, has been approved for clinical trials.
CSPC Innovation Pharmaceutical, a subsidiary of CSPC Pharma (300765.SZ), has announced that its subsidiary, Aino BioPharma Co., Ltd. ("Aino BioPharma"), has entered into a share purchase agreement with Allarity Therapeutics A/S.
CSPC Innovation Pharmaceutical (300765.SZ): The clinical trial application of SYS6023 injection from Jushi Bio has been approved by the FDA in USA.
On July 8th, GeLongHui reported that CSPC Innovation Pharmaceutical's holding subsidiary, CSPC Pharma, had received notification from the US Food and Drug Administration (FDA) that their clinical trial application for injection drug SYS6023 had been approved for clinical trials in the US. SYS6023 is a monoclonal antibody drug conjugate that can bind to a specific receptor on the surface of the tumor, enter the cell through internalization, release toxins, and achieve the effect of killing tumor cells. This product.
cspc innovation pharmaceutical (300765.SZ): Cumulative expenditure of 227 million yuan to repurchase 8.0808 million shares.
On July 1st, Gelunhui reported that CSPC Innovation Pharmaceutical (300765.SZ) repurchased 8,080,805 shares of the company's stock through a share repurchase dedicated securities account by concentrated bidding trading method, accounting for 0.58% of the company's current total share capital as of June 30, 2024. The highest fill price was 34.99 yuan/share, the lowest fill price was 18.68 yuan/share, and the total amount paid was 227 million yuan (excluding transaction fees).
CSPC Innovation Pharmaceutical (300765.SZ): Enrepta single monoclonal antibody injection of Giant Stone Biology has received conditional approval for drug listing application.
CSPC Innovation Pharmaceutical (300765.SZ) announced on June 28 that its controlling subsidiary, CSPC Pharma (Jiushi Bio) Co., Ltd. (referred to as "Jiushi Bio"), recently obtained conditional approval from the National Medical Products Administration for the listing application of Enlangsubai monoclonal antibody injection (trade name: Ensuximab). Ensuximab is a recombinant anti-PD-1 fully human monoclonal antibody of the IgG4 type that targets human programmed cell death protein-1 (PD-1) and reverses the inhibition of the immune response mediated by the PD-1 pathway, thereby activating the body's anti-tumor immune response. The product is a commodity.
No Data
